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Zerumbone (ZER) is derived from Zingiber zerumbet smith from the Zingiberaceae family. It has been 
shown to have anti-cancer and apoptosis-inducing properties against various human tumour cells. The 
aim of our study was to assess the effect of ZER on cisplatin-induced clastogenesis in Sprague-Dawley 
rat bone marrow polychromatic erythrocytes (PCEs) using micronucleus test (MN). Animals treated 
with two ZER doses for 4 consecutive days plus a single dose of cisplatin following treatment, 
presented a non-significant effects of ZER on cisplatin-induced clastogenesis. The results also 
indicated that ZER has no clastogenic effects on rat bone marrow polychromatic erythrocytes after 4 
days treatment with 250 and 500 mg/kg body weight when compared to one dose cisplatin of 45 mg/kg 
body weight. On the other hand, significant decrease in the number of PCE was observed in all 
treatment groups, indicating cytotoxicity of ZER and cisplatin. Under the present experimental 
conditions, ZER could not prevent cisplatin-induced clastogenesis in rat. 
 





Zingiber zerumbet smith is used in local traditional 
medicine to cure a number of illnesses. It is locally known 
as ‘lempoyang’ wild ginger which belongs to Zingi-
beraceae family. It is native to South East Asia but has 
been widely cultivated in village gardens throughout the 
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Abbreviation: MNPCEs, Micronuclei in polychromatic 
erythrocytes; ZER, zerumbone; CC, column chromatography; 
HPLC, high performance liquid chromatography; LCMS, liquid 
chromatography mass spectrometry; MTD, maximum tolerable 
dose; DMSO, dimethyl sulfoxide; NCE, normochromatic 
erythrocytes; PCE, polychromatic erythrocytes; MN, 
micronuclei. 
been naturalized in some areas for its medicinal proper-
ties. In some Southeast Asian countries, the rhizomes of 
the plant are employed as traditional medicines for various 
ailments, while the young shoots and inflorescence are 
used as condiments. The biologically active compound in 
Z. zerumbet called zerumbone (ZER) is one of the most 
promising chemopreventive agents against colon and 
skin cancer (Murakami et al., 2004). In addition, it was 
reported to suppress colonic tumour marker formation in 
rats, induce apoptosis in colon cancer cell lines (Murakami 
et al., 2002) and inhibit the proliferation of human colonic 
adenocarcinoma cell lines in a dose-dependent manner, 
while the growth of normal human dermal and colon fibro-
blast was less affected (Murakami et al., 2002, 2004). 
Zerumbone was further demonstrated to inhibit both 
azoxymethane-induced rat aberrant crypt foci and phor-
bol ester-induced papilloma formation in mouse skin which 





Table 1. Experimental groups and treatment protocol. 
 
Treatment Group Dose 
Control 1 No treatment 
ZER 2 250 mg/kg b.w. 
ZER 3 500 mg/kg b.w. 
DDP 4 45 mg/kg b.w. 
ZER + DDP 5 as in (2) and (4) 
ZER + DDP 6 as in (3) and (4) 




skin cancers (Murakami et al., 2004; Tanaka et al., 2001).   
Genotoxicity studies of both naturally occurring and 
synthetic substances are of great interest because of the 
widespread and often chronic use of herbal remedies, 
modern medicinal products, food ingredients, as well as 
other household and environmental chemicals. Many plant 
products contain compounds known to cause various 
diseases or even death in animals and humans (Dearfield 
et al., 2002; Ames and Gold, 1997; Raskin et al., 2002; 
Rates, 2001). Cisplatin (cis-diamminedichloroplatinum II; 
DDP) is an effective synthetic antitumor agent with a wide 
spectrum of activity against various solid tumors, but it 
has serious side effects on non-tumor cells, including free 
radical generation (Masuda et al., 1994). Cisplatin is 
highly mutagenic, inducing sister-chromatid exchanges 
and chromosomal aberrations in cultured mammalian 
cells, mouse bone marrow cells and peripheral blood 
lymphocytes in patients (Ohe et al., 1990). 
Taking into account the lack of information on in vivo 
cytogenetic effects of zerumbone, we decided to provide 
some data on the cytogenetic activity of this compound. 
Here we reported the results obtained on the cisplatin-
induced anticlastogenic effects of zerumbone in vivo 
using rat bone marrow erythrocyte micronucleus (MNPCE). 
 
 




Zerumbone was extracted in the laboratory of cancer research 
MAKNA-UPM, University Putra Malaysia, from the rhizomes of Z. 
zerumbet plant. The rhizomes were obtained from the wet market in 
Kuala Lumpur, Malaysia. Zerumbone was extracted, isolated and 
purified using methanol as an extracting solvent and column 
chromatography (CC) method. The isolated and purified zerumbone 
crystals were subjected to high performance liquid chromatography 
(HPLC) and liquid chromatography mass spectrometry (LCMS) to 
confirm its purity and molecular weight. Further, 13C NMR and 1H 
NMR analysis were conducted on the zerumbone crystals to confirm its 
molecular structure (Figure 1). A stock solution of zerumbone is 




Animals and their treatment for measurement of micronuclei in 
polychromatic erythrocytes (MNPCE)  
 
Male Sprague-Dawley rats (6 to 8 weeks old) weighing 170 to 200 g 




were obtained from the Institute of Medical Research, Kuala 
Lumpur. The rats were maintained in group per cage at room 
temperature (25 ± 1°C) and 12-h light: 12-h dark cycle, and were 
given food and water ad libitum. The animals were acclimatised for 
at least 5 days prior to dosing and were divided into seven groups 
containing 3 to 5 rats each as described in Table 1. Two dose 
levels of zerumbone (250 and 500 mg/kg) were given intraperi-
toneal for 4 consecutive days. Dose selection was based on 
preliminary experiments in which the maximum tolerable dose 
(MTD) was identified to be 1000 mg/kg body weight. An untreated 
control and a positive control (cisplatin 45 mg/kg) were also used to 
test the validity of the assay. The experiment complied with the 
guide for Animal Care and Use Committee (ACUC), Faculty of 
Medicine and Health Sciences, University Putra Malaysia. 
After the last ZER dose, 45 mg/kg cisplatin (Sigma) was given to 
all the rat groups except the vehicle control in which rats were given 
dimethyl sulfoxide (DMSO). Twenty four hours later, the animals 
were anesthetized with chloroform and sacrificed. For bone-marrow 
preparations, both hind femora were isolated and the adherent 
muscle was removed. The epiphyses were cut off and bone marrow 
cells were flushed out with foetal bovine serum (PAA Laboratories). 
The suspension of bone marrow cells and foetal bovine serum was 
centrifuged for 10 min at 1000 rpm. The resulting sediment was re-
suspended in foetal bovine serum. Bone marrow smears were pre-
pared from the resulting cell suspension. After air-drying and fixing 
for 10 min in absolute methanol, slides were stained with Giemsa-
staining method. The slides were analyzed in a blinded fashion 
using a Nikon light microscope. Both normochromatic erythrocytes 
(NCE) and polychromatic erythrocytes (PCE) were scored for bone 
marrow activity and PCEs were scored for micro-nuclei (MN). A 
total of 2000 polychromatic erythrocytes were scored per animal for 
MNPCE and 200 erythrocytes were counted for the PCE : NCE 
ratio according to the Organisation for Economic Co-operation and 
Development (OECD) guideline for testing of chemicals (mammalian 
erythrocyte micronucleus test), guideline No. 474 (OECD 1997). For 
every group of animals, the following parameters were reported: 
number of MN-containing cells/2000 PCE/animal, the number of 
PCE, the number of NCE and the NCE: PCE ratio.  
 
 
Statistical analysis  
 
Statistical analysis was performed using the Statistical Package for 
the Social Science (SPSS) 15. Rat bone marrow erythrocytes MN 
results were expressed as mean ± SE and were analyzed with one 
way analysis of variance (ANOVA), while the results from in vitro 
work were analyzed using Chi square analysis. All statistical tests 
were performed at the p < 0.05 level of significance. 
 
 
RESULTS AND DISCUSSION 
 
Micronucleus frequencies observed in polychromatic 
erythrocytes as well as the ratio of polychromatic to 
normochromatic erythrocytes of male rats are shown in 
Table 2. The exposure to the given doses of ZER resulted 
in non-significant increase in the number of micronuclei in 
polychromatic erythrocytes (MNPCEs) of both the 
exposed groups when compared to the vehicle control 
(DMSO) and negative control groups. Rats exposed to 
cisplatin showed a significant increase in the MNPCEs 
formation when compared to the negative untreated 
control and vehicle control (DMSO) groups. In addition, 
there was suppressive effect observed on pri-
administration of ZER on the cisplatin  induced  MNPCEs 




Table 2. Frequencies of MNPCE and PCE in bone marrow of rats after 4 days intraperitoneal treatment with the indicated doses of 
zerumbone and the positive control, cisplatin.  
 
Treatment Rats (no) 
MNPCE 
(Mean ± SE) 
Total MNPCE/total PCE analyzed 
(MNPCE/2000 PCE, individual data) 
Percentage 
of PCE 
Control (no treatment) 4 3.0±0.40 12/8000 (2,4,3,3) 56.5±1.1 
Cisplatin 45 mg/kg b.w. 4 7.0±0.71c 28/8000 (8,5,8,7) 24.0±3.10b 
ZER 250 mg/kg b.w. 4 1.25±0.48 5/8000 (2,1,2,0) 27.6±3.6 b 
ZER 500 mg/kg b.w. 4 2.25±0.63 9/8000 (4,2,2,1) 31.7±5.4b 
ZER 250 mg/kg + DDP 45 mg/kg b.w. 3 11.00±2.1a 33/6000 (8,15,10) 12.8±1.8 bc* 
ZER 500 mg/kg + DDP 45 mg/kg b.w. 5 11.60±2.7a 58/10000 (7,9,20,16,6) 25.2±5.5b 
Vehicle control (DMSO) 4 2.75±0.63 11/8000 (1,3,4,3) 43.62±1.8 
 
MNPCE, Micronucleated polychromatic erythrocytes; % PCE, number of PCE that were counted in microscopic fields containing 2000 NCE; 
the percentage of PCE was calculated as % PCE = [PCE / (PCE + NCE)] × 100. aP < 0.01, significantly different from control; bP < 0.001, 





Antitumor agents are known to interact with specific 
biological molecules, and evidence has been obtained 
that treatment with antitumor drugs from different cate-
gories leads to generation of free radicals in nontumor 
cells both in vivo and in vitro (Weijl et al., 1997). 
Zerumbone has gained a great attention due to its activity 
towards many diseases in vitro and in vivo. Very recently, 
Sung et al. (2009) reported zerumbone as modulator for 
osteoclastogenesis induced by RANKL and breast 
cancer. In addition, ZER was reported to effectively sup-
press mouse colon and lung carcinogenesis through 
multiple modulatory mechanisms (Kim et al., 2009). In 
cancer chemotherapy, genotoxicity effects should be 
determined before or during the phase I clinical trials 
(Pratt et al., 1994). Since the cytogenetic effects of 
zerumbone in vivo and in vitro have not been attempted 
and due to the lack of information available on the 
cytogenotoxicity of ZER, this study aims to investigate the 
effects of zerumbone that could be exerted on chromo-
somes in vivo using rat bone marrow MNPCEs test. 
As part of its preclinical safety assessment program, 
ZER was assessed for genotoxic potential by means of a 
micronucleus test in cultured human lymphocytes and 
CHO cells as well as in vivo rat bone marrow 
polychromatic erythrocyte micronucleus (PCEMN) test (Al-
Zubairi et al., 2010a, 2010b). Besides the possible use of 
ZER as a therapeutic agent, knowledge about its 
genotoxic potential is also of interest from the point of 
view of human ZER-containing food consumption. The 
use of in vivo and in vitro assays was decisive in order to 
obtain a picture of the genotoxic or anti-genotoxic 
potential of this plant product. When a bone marrow 
erythroblast develops into a PCE, the main nucleus is 
extruded and any MN that has been formed may remain 
behind in the cytoplasm. Visualisation of MN is facilitated 
in these cells because they lack a main nucleus. An 
increase in the frequency of micronucleated PCEs in 
treated animals is an indication of induced chromosomal 
damage. Genotoxic activity is normally indicated by a 
statistically significant dose-related increase in the 
incidence of micronucleated immature erythrocytes 
and/or chromosome aberrations for the treatment groups 
when compared with the concurrent control group. 
The observed inhibition of cell proliferation in the bone 
marrow illustrates the cytotoxicity of ZER. Bone marrow 
cell toxicity (or depression) is normally indicated by a 
substantial and statistically significant dose related 
decrease in the proportion of immature erythrocytes 
(PCEs); a very large decrease in the proportion would be 
indicative of a cytostatic or cytotoxic effect. However, the 
present study showed a significant decrease in the 
number of PCE (or depression in bone marrow) in all 
treatment groups of animals receiving ZER alone or ZER 
with cisplatin. This indicates that ZER and cisplatin are 
very potent inhibitors of mitosis. In the present study, the 
observed inhibition of cell proliferation in rat bone marrow 
illustrates the cytotoxicity of ZER.  
Genotoxic agents have the potential to interact with 
DNA and may cause DNA damage. Chromosomal aber-
ration that occurs in proliferating cells is regarded as a 
manifestation of damage to the genome. It has been 
commonly used as a test of mutagencity in order to 
evaluate cytogenetic responses to chemical exposure. 
Analysis of the frequency of occurrence of MNPCEs in 
bone marrow of treated animals provides a comparatively 
rapid and sensitive indication of both chromosomal 
aberrations and chromosome loss that lead to numerical 
chromosomal anomalies. An increase in the prevalence 
of MN in a population of cells indicates that chromosome 
damage has occurred as a result of an exposure that 
caused either clastogenic or an aneuploidogenic effect 
(Gonsebatt et al., 1997; Mahata et al., 2003). MN assay 
is a widely used cytogenetic method to assess in vivo 
and in vitro chromosomal damage, because this method 
is the most reproducible to show positive effects 
(Robbiano et al., 1998).  
The clastogenic action of cisplatin in somatic cells in 
vivo has already been described (Edelweiss et al., 1995). 





phases were observed to be highest at 18 and 24 h after 
cisplatin administration when compared to 72 h. It has 
been reported that antitumor agents produce a high 
frequency of aberrations in rodents 24 h after a single 
dose (Rosselli et al., 1990). The present finding shows 
that exposure to cisplatin significantly increased the 
frequency of MNPCEs in rat bone marrow when 
administered in a single dose intraperitoneally. The 
pretreatment with ZER showed no effects on cisplatin-
induced formation of MNPCEs in the rat bone marrow. 
In conclusion, our in vivo clastogenesis studies found 
out that zerumbone could be cytotoxic without any 
anticlastogenic potential against cisplatin induced clasto-
genesis. However, it is important to carry out more 
investigations using various cytogenetic tests under 
different experimental conditions to get more information 
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